Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin PK and DDI with Rifampicin
NCT04080609Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Hua Medicine. Primary endpoints: Maximum Plasma Concentration up to 96 hours and Area Under the Curve to Last Measurable Concentration up to 96 hours. Started Mar 2018; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04080609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080609.